Sodium Acetate Ameliorates Doxorubicin-induced Cardiac Injury Via Upregulation of Nrf2/HO-1 Signaling and Downregulation of NFkB-mediated Apoptotic Signaling in Wistar Rats
Overview
Authors
Affiliations
Despite the effectiveness of doxorubicin (DOX) in the management of a wide range of cancers, a major challenge is its cardio-toxic effect. Oxidative stress, inflammation, and apoptosis are major pathways for the cardiotoxic effect of DOX. On the other hand, acetate reportedly exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. This particular research assessed the impact of acetate on cardiotoxicity induced by DOX. Mechanistically, acetate dramatically inhibited DOX-induced upregulation of xanthine oxidase and uric acid pathway as well as downregulation of Nrf2/HO-1 signaling and its upstream proteins (reduced glutathione peroxidase, superoxide dismutase, glutathione-S-transferase, glutathione, and catalase, glutathione reductase). In addition, acetate markedly attenuated DOX-driven rise inTNF-α, NFkB IL-6 and IL-1β expression, and myeloperoxidase activity. Furthermore, acetate significantly ameliorated DOX-led suppression of Bcl-2 and Ca-ATPase activity and upregulation of Bax, caspase 3, and caspase 9 actions. Improved body weight, heart structural integrity, and cardiac function as depicted by cardiac injury markers convoyed these cascades of events. Summarily, the present study demonstrated that acetate protects against DOX-induced cardiotoxicity by upregulating Nrf2/HO-1 signaling and downregulating NFkB-mediated activation of Bax/Bcl-2 and caspase signaling.
Besong E, Akhigbe T, Oyedokun P, Hamed M, Akhigbe R Toxicol Res. 2024; 40(4):613-626.
PMID: 39345745 PMC: 11436558. DOI: 10.1007/s43188-024-00250-3.
Mannino F, Urzi Brancati V, Lauro R, Pirrotta I, Rottura M, Irrera N Biomedicines. 2024; 12(5).
PMID: 38790971 PMC: 11117907. DOI: 10.3390/biomedicines12051009.
Xie X, Wang Y, Ma F, Ma R, Du L, Chen X Mar Biotechnol (NY). 2024; 26(3):526-538.
PMID: 38647909 DOI: 10.1007/s10126-024-10315-x.
Targeting cardiovascular risk factors with eugenol: an anti-inflammatory perspective.
Devi S, Chauhan S, Mannan A, Singh T Inflammopharmacology. 2023; 32(1):307-317.
PMID: 38085446 DOI: 10.1007/s10787-023-01392-w.